Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

NEUROCRIN Form 4 May 27, 2005	E BIOSCIENC	CES INC									
FORM	Δ								PPROVAL		
Check this box UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box StateMent of Section 16. Section 16. StateMent of Section 16. Form 4 or Form 5 obligations may continue. Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 1940								N OMB Number:	3235-0287		
								Estimated burden hou response	Estimated average burden hours per response 0.5		
See Instruct 1(b).	tion	50(II)	of the f	livesulleli	a Compa	IIY ACT OF	1940				
(Print or Type Rea	sponses)										
1. Name and Address of Reporting Person <u>*</u> POPS RICHARD F			2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES			-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last)	(First) (Middle)	INC [NBIX]				X Director 10% Owner				
ALKERMES,	(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) LKERMES, INC., 88 SIDNEY 05/25/2005 FREET, 2ND FLR					Officer (giv below)		ner (specify			
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)				al	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 						
CAMBRIDGE, MA 02139							Person				
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	e Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
	Transaction Date Ionth/Day/Year)		Date, if	Code (Instr. 8)	4. Securi onAcquired Disposed (Instr. 3, Amount	l (A) or l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Repor	t on a separate line	e for each cl	ass of sec	urities bene	eficially ow	ned directly	or indirectly.				
Persons who respond to the collect information contained in this form a required to respond unless the form displays a currently valid OMB con number.							n are not rm	SEC 1474 (9-02)			
	Tab					sposed of, or convertible	· Beneficially Owner securities)	d			

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ear)	(Instr. 3 and 4)	
				Code V	(A) (E	D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (1)	\$ 37.37	05/25/2005		A	12,000	06/25/2005	05/25/2015	Common Stock	12,000

Reporting Owners

Reporting Owner Name / Address						
	Director	10% Owner	Officer	Other		
POPS RICHARD F ALKERMES, INC. 88 SIDNEY STREET, 2ND FLR CAMBRIDGE, MA 02139	Х					
Signatures						
Margaret E. Valeur-Jensen, by Pow Attorney	ver of	02/25/2005				
** Signature of Reporting Person		Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents option of which 1/12th of the shares underlying the option becomes vested and exercisable on June 25, 2005, an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.